基于真实世界的中重度斑块型银屑病患者治疗模式与疾病负担研究OA

Objective To investigate the treatment patterns and disease burden of patients with moderate-to-severe plaque psoriasis.Methods A retrospective analysis was conducted on the general demographics,clinical characteristics,treatment patterns,clinical outcomes,direct medi-cal costs,and healthcare resource utilization(HCRU)of patients with moderate-to-severe plaque psoriasis treated at the Department of Dermatology,Hospital of Dermatology,Chinese Academy of Medical Sciences,and the Department of Dermatology,Beijing Friendship Hospital,Capital Med-ical University,from January 2018 to December 2021.Additionally,a questionnaire survey was administered to patients with moderate-to-severe plaque psoriasis visiting the dermatology depart-ments of these two hospitals between October 2022 and March 2023 to collect data on their base-line characteristics and treatment history.Results A total of 1,102 patients were included in the retrospective analysis,with a mean age of 44.90±14.64 years,of whom 77.22％were male and 22.78％were female.During the observation period,87.84％of patients discontinued systemic therapy.The average annual outpatient visits per patient were 6.47±5.21.Among inpatients(n=118),the average annual duration of hospital stay was 9.29 days,and the average direct med-ical cost was(371.09±141.56)RMB per month.The cross-sectional survey included 380 pa-tients,of whom 62.17％received only topical treatment and 17.72％were treated with biologics.Additionally,75.26％of patients had fully adhered to their treatment plan in the past six months.However,42.11％of patients expressed dissatisfaction or a neutral attitude toward treatment efficacy and safety.According to the EQ-5D-3L assessment results,nearly one-third of patients reported symptoms of anxiety or depression.Conclusions Patients with moderate-to-se-vere plaque psoriasis predominantly receive topical therapy,yet bear a substantial disease burden and experience poor health-related quality of life.It is recommended to further improve patient care and enhance disease management capabilities by increasing reimbursement rates under medi-cal insurance schemes and developing standardized clinical practice guidelines.